BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Eli Lilly to restructure, bet on drug portfolio]]>http://www.bloggingstocks.com/2009/09/15/eli-lilly-to-restructure-bet-on-drug-portfolio/http://www.bloggingstocks.com/2009/09/15/eli-lilly-to-restructure-bet-on-drug-portfolio/http://www.bloggingstocks.com/2009/09/15/eli-lilly-to-restructure-bet-on-drug-portfolio/#commentsFiled under: , ,

Pharmaceutical company Eli Lilly & Co. (NYSE: LLY) is planning to cut 5,500 jobs over the next few years and reorganize into five business units. The company is looking to reduce costs and accelerate how long it takes new drugs to get to market, especially as its top performers see their patents expire. This translates to a workforce reduction of close to 14% - to 35,000. This measure doesn't include new positions in emerging markets with high potential and Japan.

The company hopes to cut as much as possible through attrition and retirements - and it would not indicate how many other positions would have to be cut.

Eli Lilly's goal is to slash its annual cost by $1 billion during this restructuring. The new business units will be: cancer, diabetes, established markets, emerging markets and Elanco, which is its animal health business. This is a change from the existing functional model, which separates U.S. and global marketing for each drug in the company's portfolio. Through the new structure, Lilly says, drug development and marketing will be tied more closely.

Continue reading Eli Lilly to restructure, bet on drug portfolio

Eli Lilly to restructure, bet on drug portfolio originally appeared on BloggingStocks on Tue, 15 Sep 2009 10:40:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>cancercancer drugsCancerDrugscymbaltadiabetesdiabetes drugsDiabetesDrugseli lillyeli lilly and coemerging marketsEmergingMarketsfeaturedgemzarhumalogllymultiple sclerosisnew drugsNewDrugspharmaceutical stockspharmaceuticalsPharmaceuticalStockszyprexaTue, 15 Sep 2009 10:40:00 EST<![CDATA[Time to scoop up some shares of Lilly]]>http://www.bloggingstocks.com/2009/06/08/time-to-scoop-up-some-shares-of-lilly/http://www.bloggingstocks.com/2009/06/08/time-to-scoop-up-some-shares-of-lilly/http://www.bloggingstocks.com/2009/06/08/time-to-scoop-up-some-shares-of-lilly/#commentsFiled under: ,

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with the aforementioned in mind, Eli Lilly & Co. (NYSE: LLY) is worth a review.

In general, analysts see a 5-7% revenue gain in FY2009 for Lilly, led by growth in sales of branded drugs Cymbalta, Humalog, Cialis, and Alimta. Meanwhile, sales of Zyprexa and Gemzar are likely to decline this year.

Continue reading Time to scoop up some shares of Lilly

Time to scoop up some shares of Lilly originally appeared on BloggingStocks on Mon, 08 Jun 2009 18:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>alimtacialiscymbaltagemzarhumalogzyprexaMon, 08 Jun 2009 18:00:00 EST